X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (54) 54
index medicus (52) 52
oncology (43) 43
cancer (39) 39
male (30) 30
female (29) 29
middle aged (27) 27
aged (25) 25
chemotherapy (22) 22
adult (20) 20
tumors (19) 19
lung cancer (18) 18
mutation (16) 16
aged, 80 and over (15) 15
lung neoplasms - genetics (15) 15
care and treatment (14) 14
survival (13) 13
therapy (13) 13
hematology, oncology and palliative medicine (12) 12
lung cancer, non-small cell (12) 12
lung neoplasms - drug therapy (12) 12
analysis (11) 11
antineoplastic agents - therapeutic use (11) 11
carcinoma, non-small-cell lung - drug therapy (11) 11
carcinoma, non-small-cell lung - genetics (11) 11
genomics (11) 11
immunotherapy (11) 11
patients (11) 11
cell biology (10) 10
clinical trials (10) 10
lung neoplasms - pathology (10) 10
metastasis (10) 10
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
cancer therapies (9) 9
expression (9) 9
lung neoplasms - mortality (9) 9
medicine & public health (9) 9
treatment outcome (9) 9
animals (8) 8
carcinoma, non-small-cell lung - mortality (8) 8
disease-free survival (8) 8
genetic aspects (8) 8
medical research (8) 8
medicine (8) 8
pharmacology & pharmacy (8) 8
research (8) 8
research article (8) 8
abridged index medicus (7) 7
breast-cancer (7) 7
carcinoma, non-small-cell lung - pathology (7) 7
medicine, experimental (7) 7
medicine, general & internal (7) 7
neoplasms - drug therapy (7) 7
neoplasms - genetics (7) 7
prognosis (7) 7
risk factors (7) 7
young adult (7) 7
antineoplastic agents - adverse effects (6) 6
biomarkers, tumor - genetics (6) 6
breast cancer (6) 6
cell lung-cancer (6) 6
cisplatin - administration & dosage (6) 6
colorectal-cancer (6) 6
epidermal growth factor (6) 6
gene expression (6) 6
kaplan-meier estimate (6) 6
life sciences (6) 6
lymphocytes (6) 6
melanoma (6) 6
metastases (6) 6
mutations (6) 6
neoplasm staging (6) 6
pd-l1 protein (6) 6
pharmacology/toxicology (6) 6
prospective studies (6) 6
solid tumors (6) 6
toxicity (6) 6
adenocarcinoma (5) 5
apoptosis (5) 5
bevacizumab (5) 5
biology (5) 5
biopsy (5) 5
carcinoma (5) 5
complications and side effects (5) 5
deoxyribonucleic acid--dna (5) 5
drug therapy (5) 5
egfr (5) 5
gene (5) 5
genes (5) 5
genetics (5) 5
health aspects (5) 5
internal medicine (5) 5
lung neoplasms - therapy (5) 5
open-label (5) 5
pembrolizumab (5) 5
precision medicine (5) 5
proteins (5) 5
safety (5) 5
studies (5) 5
targeted therapy (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10072, pp. 917 - 929
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 897 - 907
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10026, pp. 1415 - 1426
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 990 - 998
Summary Background Optimum management strategies for patients with advanced non-small-cell lung cancer (NSCLC) with acquired resistance to EGFR tyrosine-kinase... 
Hematology, Oncology and Palliative Medicine | TYROSINE KINASE INHIBITORS | MULTICENTER | ONCOLOGY | ADENOCARCINOMA | ACQUIRED-RESISTANCE | OPEN-LABEL | AFATINIB | ERLOTINIB | GEMCITABINE | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Receptor, Epidermal Growth Factor - metabolism | Time Factors | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Glutamates - administration & dosage | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Infusions, Intravenous | Mutation | Guanine - administration & dosage | Medical colleges | Chemotherapy | Strategic planning (Business) | Genetic aspects | Product development | Lung cancer, Non-small cell | Gefitinib | Cancer
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 382, Issue 9893, pp. 709 - 719
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2015, Volume 372, Issue 21, pp. 2018 - 2028
Journal Article
Science, ISSN 0036-8075, 01/2018, Volume 359, Issue 6371, pp. 91 - 97
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce sustained clinical responses in a sizable minority of cancer patients. We found that... 
CELL LUNG-CANCER | MELANOMA | MICROENVIRONMENT | INTESTINAL MICROBIOTA | CYCLOPHOSPHAMIDE | PD-1 BLOCKADE | MULTIDISCIPLINARY SCIENCES | GENES | RESISTANCE | ANTITUMOR IMMUNITY | NIVOLUMAB | CD4 Antigens - immunology | Immunotherapy - methods | Humans | Antibodies, Monoclonal - therapeutic use | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Gastrointestinal Microbiome - genetics | Fecal Microbiota Transplantation | Anti-Bacterial Agents - therapeutic use | Feces - microbiology | Metagenome - genetics | Neoplasms - therapy | Animals | Receptors, CCR - immunology | Interleukin-12 - immunology | Receptors, CXCR3 - immunology | T-Lymphocytes - immunology | Mice | Gastrointestinal Microbiome - immunology | Verrucomicrobia - genetics | Verrucomicrobia - immunology | Care and treatment | Cell receptors | Microbiota (Symbiotic organisms) | Immunotherapy | Epithelial tumors | Physiological aspects | Health aspects | Methods | Apoptosis | PD-1 protein | Interleukin | Microbiomes | Transplantation | Lymphocytes T | Anticancer properties | Microbiota | Lymphocytes | Bacteria | Feces | Supplementation | Gnotobiotics | Kidneys | Melanoma | Dietary supplements | Interleukin 12 | Abundance | CXCR3 protein | Patients | CD4 antigen | Immune checkpoint | Antibiotics | Lungs | Flora | PD-L1 protein | Relative abundance | Antitumor activity | CCR9 protein | Tumors | Kidney transplantation | Cancer | Life Sciences
Journal Article
Science Translational Medicine, ISSN 1946-6234, 10/2013, Volume 5, Issue 209, pp. 209ra153 - 209ra153
We characterized genome alterations in 1255 clinically annotated lung tumors of all histological subgroups to identify genetically defined and clinically... 
GEFITINIB | FUSION | GENE | ADENOCARCINOMA | OPEN-LABEL | SQUAMOUS-CELL CARCINOMAS | HUMAN CANCER | ACTIVATING MUTATIONS | DRIVER MUTATIONS | EGFR | MEDICINE, RESEARCH & EXPERIMENTAL | NRF2 | CANCER | CELL BIOLOGY | Lung Neoplasms - genetics | Lung Neoplasms - classification | Automation | Genomics | Humans | Lung Neoplasms - pathology | Lung Neoplasms - diagnosis | Genome, Human - genetics
Journal Article
10.